Androgen in Medical Technology

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

... 1-2 trial evaluating MDV3100, a next-generation androgen receptor antagonist, in castration-resistant ... contrast to those achieved with first-generation androgen receptor antagonists." In vitro data ... mechanism of action is unlike that of the leading androgen receptor antagonist, bicalutamide. Specifically, ...

Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy

... investigate the use of degarelix for intermittent androgen deprivation therapy (IADT) in patients with ... The study will compare IADT to continuous androgen deprivation therapy (ADT) for 14 months with ... measured by PSA suppression. "Intermittent androgen deprivation therapy is a commonly employed ...

AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne

... and commercialization. Through enhancing androgen receptor protein degradation, ASC-J9(TM) ... effect of androgens (male hormones), through the androgen receptor, a key causative factor in the ... mechanism of action, which selectively enhances androgen receptor degradation (ARD) to ...

Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

... a poor prognosis. Overexpression of the androgen receptor is believed to contribute to ... cancer. MDV3100 is a novel small-molecule androgen receptor antagonist that inhibits androgen receptor function by blocking nuclear ...

Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions

... from its internal nonsteroidal selective androgen receptor modulator ("SARM") discovery program, ... trials in 2009." About SARMs Selective androgen receptor modulators (SARMs) are a novel class ... androgen receptors to promote or inhibit specific androgen action in different tissues. SARMs have the ...

Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy

... Findings suggest androgen production occurs within metastatic prostate ... found that despite the suppression of circulating androgen levels to very low or castrate levels, metastatic ... prostate tissue in men with normal circulating androgen levels (collected at the time of ...

Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease

... - Adding Bavituximab to Standard Regimen of androgen Deprivation and Chemotherapy Reduced Size of ... in mice when added to a standard regimen of androgen deprivation and docetaxel. The study findings ... failing to respond to the standard combination of androgen deprivation and chemotherapy drugs such ...

Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors

... - Adding Bavituximab to Standard Regimen of androgen Deprivation and Chemotherapy Reduced Size of ... in mice when added to a standard regimen of androgen deprivation and docetaxel. The study findings ... failing to respond to the standard combination of androgen deprivation and chemotherapy drugs such ...

Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting

... that data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist, MDV3100, showed encouraging anti-tumor activity as ... stabilization, after three months of treatment. An increased number of androgen receptors present on prostate cancer cells is believed to play a major ...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

... to grow despite current standard of care hormonal (anti-androgen) therapies. CRPC is more invasive and more likely to spread to other organs than androgen dependent prostate cancers. Patients with CRPC have few treatment options and a poor prognosis. About Picoplatin Picoplatin is ...

Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology

... to grow despite current standard of care hormonal (anti-androgen) therapies. CRPC is more invasive and more likely to spread to other organs than androgen dependent prostate cancers. Patients with CRPC have few treatment options and a poor prognosis. About Colorectal Cancer CRC is the third ...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

... that converts testosterone to DHT, D-3263 is not an inhibitor of this enzyme suggesting that the two agents may act by different means to affect androgen metabolism and prostate hyperplasia. "BPH is a condition that affects a significant number of men, and based on the preclinical data announced ...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

... reported that similar to bavituximab, the human antibody PGN635 targets and binds specifically to the tumor vascular endothelium(1). Treatment with androgen deprivation therapy or docetaxel substantially increased the percentage of tumor blood vessels with PGN635 binding. The researchers also ...

Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million

... study in the first quarter of 2009. In addition, the company recently announced selection of the first preclinical candidate from its SARM (selective androgen receptor modulator) discovery program for treatment of muscle loss, with an investigational new drug (IND) filing expected in the second quarter of ...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

... Texas Oncology-Deke Slayton Cancer Center: Phase II study of Azacitidine for castration-resistant prostate cancer progressing on combined androgen blockade -- Phillip Periman, M.D., Texas Oncology-Amarillo: Phase II study of Sunitinib malate for metastatic castration-resistant prostate ...

Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting

... May 15 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that data from an ongoing Phase 1-2 clinical trial of its novel androgen receptor antagonist, MDV3100, will be presented in an oral presentation at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in ...

Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival

... important baseline prognostic factors. The abstract (#21), "Cell Number and CD54 Expression in Sipuleucel-T Correlate with Survival in Metastatic androgen Independent Prostate Cancer," is being presented at the American Society of Clinical Oncology's 2008 Genitourinary Symposium in San Francisco. In ...

Testosterone May Improve Mental Function, From the Harvard Men's Health Watch

... effects as well. Harvard Men's Health Watch suggests that until more research findings are available, men should not use testosterone or any other androgen to improve mental function. Also in this issue: -- Red meat and colon cancer -- Napping your way to health -- On Call: Is smoking in low ...

Male Birth Control Pill, Blackberry Extract for Gingivitis, Skin Cancer and Digestive Health Top List of New Medical Discoveries

... have been examining the reversibility of a compound that inhibits infertility by utilizing a non-steroidal hormonal therapy known as a selective androgen receptor modulator. "Past clinical studies using testosterone for male contraception were not effective at preventing pregnancy without producing ...

Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial

... at 8:30 A.M. Eastern time - SAN FRANCISCO, Nov. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that its selective androgen receptor modulator, MDV3100, to date has reduced serum levels of prostate specific antigen (PSA), a marker of tumor growth, in the six patients ...

Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine

... chemotherapy for this condition. Prostate Cancer Taxotere(R) in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Gastric Cancer Taxotere(R) in combination with cisplatin and fluorouracil is ...

GTx Announces Ostarine Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial

... Ostarine, the company's first-in-class selective androgen receptor modulator (SARM). In the three month ... for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, ... Ostarine(TM), a first-in-class selective androgen receptor modulator, or SARM. GTx plans to ...

GTx Announces Presentation of Ostarine and Acapodene Data at 2007 ASCO Annual Meeting

... Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal ... GTx also is developing Ostarine(TM), a first-in-class selective androgen receptor modulator, or SARM. GTx plans to initiate a Phase IIb ...

New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

... be suffering from low testosterone should talk to their doctors about the androgen Deficiency in Aging Men (ADAM) questionnaire. The ADAM questionnaire ... Clinical Guidelines: Testosterone Therapy in Adult Men with androgen Deficiency Syndrome: An Endocrine Society Clinical Practice ...

Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference

... place. The poster presentations are further detailed below: Inhibition of androgen synthesis results in high response rate in castration resistant prostate ... with castration resistant prostate cancer who have failed treatment with androgen deprivation therapy and failed treatment with first line docetaxel-based ...

Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session

... as part of a special session, Phase II Proof of Concept Late-Breaking Clinical Trials. These presentations are further detailed below: Inhibition of androgen synthesis results in a high response rate in castration refractory prostate cancer: A Phase II clinical trial The Phase I/II trial of CB7630 was ...

Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting

... UK Centre for Cancer Therapeutics at The Institute of Cancer Research in an oral presentation entitled, "Abiraterone acetate, an inhibitor of androgen synthesis, has significant antitumor activity in castration resistant prostate cancer." The Phase I/II trial of CB7630 was conducted at The ...

Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy

... A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine as First Line Chemotherapy in Patients with androgen Independent Prostate Cancer. J. Urol., DOI:10-1016/j.juro.2007.01.148 Available to download at:

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

... chemotherapy for this condition. Prostate Cancer Taxotere(R) in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Gastric Cancer Taxotere(R) in combination with cisplatin and flourouracil ...

Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting

... In his poster, Dr Attard also provided an update on the Phase II trial of CB7630 in patients with advanced prostate cancer who have failed androgen deprivation and docetaxel-based chemotherapy. The Phase II trial is being conducted at numerous locations in the United States and United Kingdom. In ...

Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer

... p=0.004). The once every three weeks 75mg/m2 Taxotere(R) (docetaxel) plus 5 mg prednisone regimen has been approved for use as a treatment for androgen independent (hormone-refractory) metastatic prostate cancer in the U.S. since May 2004 and October 2004 in Europe. It is the only standard of care ...